German pharmaceutical firm BioNTech, one of the first companies worldwide to develop an effective coronavirus vaccine, is looking to acquire its domestic rival CureVac, the firm said on Thursday ...

BERLIN — The German state of Berlin is again suspending the use of AstraZeneca’s coronavirus vaccine for people under 60 due to additional reports of blood clots.

BioNTech is buying fellow German mRNA vaccine developer CureVac in an all-stock transaction that values the acquired biotech at $1.25 billion. The announcement makes no specific mention of ...

The German state of Berlin is again suspending the use of AstraZeneca’s coronavirus vaccine for people under 60 due to additional reports of blood clots.